BOSTON (Reuters) – Sanofi-Aventis SA pitched a new offer to acquire U.S. biotechnology company Genzyme Corp for $71 a share in exchange for the opportunity to conduct “partial due diligence,” according to DealReporter, which cited a source close to the discussions.

Read More

Comments are closed.